H5N1 News and Research RSS Feed - H5N1 News and Research Twitter

Influenza A (H5N1) virus – also called “H5N1 virus” – is an influenza A virus subtype that occurs mainly in birds, is highly contagious among birds, and can be deadly to them. H5N1 virus does not usually infect people, but infections with these viruses have occurred in humans. Most of these cases have resulted from people having direct or close contact with H5N1-infected poultry or H5N1-contaminated surfaces.
Sinovac selected to supply seasonal influenza vaccine to Beijing citizens

Sinovac selected to supply seasonal influenza vaccine to Beijing citizens

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention to be a supplier of the seasonal influenza vaccine to the citizens of Beijing for 2014. [More]
CDC closes labs after anthrax, flu accidents

CDC closes labs after anthrax, flu accidents

Federal government labs in Atlanta were temporarily shut after it was discovered they had improperly sent potentially deadly pathogens, including anthrax, botulism and virulent bird flue virus, to other labs. [More]
First Edition: July 14, 2014

First Edition: July 14, 2014

Today's headlines include coverage of Medicare, the health law and veterans' care policy issues as well as reports from the campaign trail. [More]
PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

PaxVax partners with UC to develop combination vaccine to prevent genital HSV infections

PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced that it has entered into a research and development collaboration with the University of California, San Diego to develop a combination vaccine to prevent genital herpes simplex virus (HSV) infections. [More]
Nanoviricides develops new drug candidates against MERS infection

Nanoviricides develops new drug candidates against MERS infection

... [More]
Biotech to the rescue

Biotech to the rescue

MIT professor Ram Sasisekharan's three biotech companies — Momenta Pharmaceuticals, Cerulean Pharma, and Visterra — share a similar goal. [More]
Sinovac Biotech commits to commercialize Sabin Inactivated Polio Vaccine in China

Sinovac Biotech commits to commercialize Sabin Inactivated Polio Vaccine in China

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China that focuses on the research, development, manufacturing and commercialization of vaccines, announced today that it has entered into a license agreement with Intravacc (Institute for Translational Vaccinology) from The Netherlands to develop and commercialize the Sabin Inactivated Polio Vaccine (sIPV) for distribution to China and other countries. [More]
PeptiDream develops novel macrocyclic peptide inhibitor for treatment of multiple influenza strains

PeptiDream develops novel macrocyclic peptide inhibitor for treatment of multiple influenza strains

PeptiDream Inc., a public Tokyo-based biopharmaceutical company ("PeptiDream")( TOKYO:4587) announced today, in collaboration with The Tokyo Metropolitan Institute of Medical Science ("Tokyo Metropolitan Institute") the discovery and development of a novel macrocyclic peptide inhibitor for the treatment of multiple influenza strains. [More]
Scientists map key elements of immune overreaction triggered by influenza virus infection

Scientists map key elements of immune overreaction triggered by influenza virus infection

Scientists at The Scripps Research Institute (TSRI) have mapped key elements of a severe immune overreaction—a "cytokine storm"—that can both sicken and kill patients who are infected with certain strains of flu virus. [More]
TSRI scientists describe severe immune overreaction caused by flu infections

TSRI scientists describe severe immune overreaction caused by flu infections

Scientists at The Scripps Research Institute have mapped key elements of a severe immune overreaction—a “cytokine storm”—that can both sicken and kill patients who are infected with certain strains of flu virus. [More]
Upstream interventions may provide options to contain emerging pathogens at source

Upstream interventions may provide options to contain emerging pathogens at source

While many endemic infectious diseases of humans have been largely contained, new microbes continue to emerge to threaten human and animal health. [More]
New study tracks spread of H5N1 variant in Egypt recently identified as major epicenter for virus

New study tracks spread of H5N1 variant in Egypt recently identified as major epicenter for virus

Since its first identification in Asia, highly pathogenic avian influenza-H5N1-has caused significant alarm in the scientific community. While the virus' primary target is birds-tens of millions have already died from it-it is capable of infecting mammals, including humans, causing serious illness and a frightening rate of mortality. [More]
Chinese scientists confirm world’s first case of human infection with new avian influenza virus

Chinese scientists confirm world’s first case of human infection with new avian influenza virus

Scientists from China report in The Lancet on the world’s first confirmed case of human infection with a new avian influenza A H10N8 virus in a 73-year-old woman who died from the infection. [More]
Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing live attenuated influenza vaccines against seasonal and pandemic influenza, today announced that it has signed a Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to generate and evaluate in preclinical studies LAIV candidates against influenza A(H7N9). [More]
PaxVax reports interim data from Phase 3 cholera challenge study of PXVX0200

PaxVax reports interim data from Phase 3 cholera challenge study of PXVX0200

PaxVax Inc, which develops and commercializes innovative vaccines against infectious diseases in a socially responsible manner, today announced interim data from a Phase 3 cholera challenge study of its single-dose oral cholera vaccine candidate, PXVX0200 (also known as CVD 103-HgR). Trial investigators compared the rate of diarrhea in participants vaccinated with PXVX0200 to the rate in participants who had received placebo. [More]
CEL-SCI closes public offering of common stock, exercises over-allotment option to purchase additional shares

CEL-SCI closes public offering of common stock, exercises over-allotment option to purchase additional shares

CEL-SCI Corporation, a late-stage oncology company, today announced that it has closed an underwritten public offering of units consisting of an aggregate of 5,238,095 shares of common stock and warrants to purchase an aggregate of 5,238,095 shares of common stock. The [More]
ATS Labs offers testing of antimicrobial products for efficacy against H7N9 virus

ATS Labs offers testing of antimicrobial products for efficacy against H7N9 virus

ATS Labs announced today that they are pleased to offer testing of antimicrobial products for efficacy against avian influenza A (H7N9) virus. Avian influenza A (H7N9) virus, called H7N9 for short, has infected humans in China causing severe respiratory illness. [More]
CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

CEL-SCI gets approval to start enrollment for Multikine Phase III study for head and neck cancer

Further advancing one of the largest Phase III trials for head and neck cancer in the world, CEL-SCI Corporation announced today that it has received approval from the Agency for Medicaments and Medical Devices of the government of Bosnia and Herzegovina to begin enrollment of subjects into the Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine (Leukocyte Interleukin, Injection). [More]
European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

NanoViricides, Inc. announced today that the European Medicines Agency, has awarded orphan drug designation to DengueCide, the Company's drug candidate for the treatment of dengue and dengue hemorrhagic fever. [More]
Scientists highlight novel way to develop universal influenza vaccine that can protect against multiple flu strains

Scientists highlight novel way to develop universal influenza vaccine that can protect against multiple flu strains

A study led by St. Jude Children's Research Hospital scientists highlights a new approach for developing a universal influenza vaccine that could protect against multiple flu strains, including deadly pandemic strains. The research appears today in the advance online edition of the scientific journal Nature Immunology. [More]